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The phannacokinetics of a syrup formulation consisting of four parts of amoxycillin
and one part of potassium clavulanate (Augmentin) were studied in 11 paediatric
patients, 3 to 14 years of age. Single oral doses of 25 mg of Augmentin per kg body
weight (20 mg of amoxycillin per kg plus 5 mg of potassium clavulanate per kg, i.e.
1 mg of the syrup per kg) were administered on an empty stomach, and were well
accepted and tolerated. Mean peak plasma concentrations 60-90 min after dosing
were 7-2 mg/1 for amoxycillin and 2-0 mg/1 for clavulanic acid. Mean terminal phase
plasma half-Iifes were 1-4 and 1-0 h, respectively. It is concluded that 25-mg/kg doses
of this syrup formulation of Augmentin administered three times daily should be
adequate therapy for various childhood bacterial infections.
Introduction
Clavulanic acid protects amoxycillin against hydrolysis by /Mactamases produced by
many important pathogens causing paediatric infectious diseases (Hunter et al., 1980;
Reading, Farmer & Cole, 1983). The considerable amount of data reported on
pharmacokinetics and clinical experience with amoxycillin-clavulanic acid suggests that
the two compounds are pharmacokinetically compatible and that this antimicrobial
combination is effective and safe therapy for urinary-tract, respiratory-tract, middle-ear,
skin, soft-tissue and intra-abdominal infections caused by susceptible bacteria (Stein &
Gurwith, 1984; Odio et al., 1985).
The purpose of the present study was to evaluate the pharmacokinetics of a syrup
formulation consisting of four parts of amoxycillin and one part of clavulanic acid in
paediatric patients. Both the presentation in powder sachets and the fruit-flavoured taste
of the syrup suspension were specially developed for paediatric use.
Materials and methods
Study patients
Pharmacokinetic studies following the oral administration of a single dose of
amoxycillin-potassium clavulanate were performed in 11 paediatric patients treated at
the Department of Paediatrics, University of Berne, for various non-bacterial diseases.
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None of the 11 patients, 7 females and 4 males, had received antimicrobial therapy for at
least 72 h before the study. Ages ranged between 31 and 13-8 years (mean±s.D.,
10-8 ±3-2 years). They had no medical history of previous allergy to /2-lactam
compounds, nor of renal or hepatic diseases. Clinically, their hydration and circulation
status was judged to be normal. The study protocol was approved by the Institutional
Committee on Human Investigations, Department of Paediatrics, University of Berne,
and informed parental consent was obtained for all study patients.
Drug administration
Syrup sachets contained 250 mg of amoxycillin and 62-5 mg of potassium clavulanate
(Augmentin Sachet, 312-5 mg, batch no C.T. 11942; Beecham Pharmaceuticals,
Worthing, England). The complete contents were emptied immediately before use into
100 ml of water, resulting in 12-4 ml of syrup suspension containing 20 mg of amoxy-
cillin and 5 mg of potassium clavulanate per ml. On an empty stomach 1 ml of the syrup
per kg body weight (20 mg amoxycillin per kg plus 5 mg clavulanic acid per kg) was
administered followed by drinking a cupful of water. Adverse reactions (local or
systemic) to Augmentin were assessed by clinical observation.
Collection of biological samples
Blood samples for drug assays were collected from an intravenous heparin lock
immediately before the oral dose (predose sample) and at 20, 40, 60, 90, 120, 180 and
360 min after drug administration. The blood was immediately mixed with sodium
citrate and kept in the refrigerator (4°C) until centrifuged within 30 min. Plasma samples
were stored at — 70°C until assayed within one week of collection.
The total urine was collected from 9 of the 11 patients at the following time intervals:
— 1 to 0, 0 to 2, 2 to 4, and 4 to 6 h after dosing. Urine was sampled from a sterile collec-
tion bag (three patients) or by voluntary voiding (six patients). Volumes were recorded,
and a 1-ml aliquot from each collection period was mixed with 9 ml of 01 M citrate
buffer pH 6-5 and stored at — 70°C until assayed within one week of collection.
Antibiotic assays
Amoxycillin was assayed with a standard large plate well diffusion technique using
Sarcina lutea (NCTC 8340) as the assay organism. Clavulanic acid concentrations were
measured by microbiological assay Klebsiella aerogenes (NCTC 11228) as the assay
organism (Schaad, Casey & Cooper, 1983).
Pharmacokinetic analysis
Model-independent pharmacokinetic data were determined for amoxycillin and
clavulanic acid.
Results
Plasma concentrations
Mean plasma concentrations (±s,D.) of amoxycillin and clavulanic acid are shown in
Table I. Predose samples were free of either agent. Peak plasma concentrations of each
drug were found in most patients 60 or 90 min after the dose, with a range of from 40 to
120 min. Mean peak concentration was 7-23 mg/1 for amoxycillin at 60 min, and
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Table I. Plasma concentrations and ratios of amoxycillin and clavulanic acid in 11 paediatric
patients
Drug
amoxycillin
clavulanic
acid
ratio of amoxycillin
to clavulanic acid
Dosage
(mg/kg)
20
5
Mean (±SJ>.) plasma concn (mg/1) and ratios at indicated times
after dose
213
(1-75)
0-85
(0-89)
2-5
5-58
(3-83)
1-72
(1 21)
3-2
7-23
(4-61)
200
(102)
3-6
713
(3-83)
204
(0-71)
3-5
6-23
(2-61)
1-60
(0-65)
3-9
4-54
(1-59)
0-79
(0-50)
5-7
1-74
(1-36)
012
(010)
14-5
Table II. Per cent recovery of amoxycillin and clavulanic acid in
the urine of 9 paediatric patients
Dosaee °/o recovery (±s-0-) " * u r i n e a t
Drug , n°. indicated time intervals after dose
(mg/kg)
 Q _ 2 h 2 _ 4 h 4 _ 6 h Q_6h
amoxycillin
clavulanic
acid
20
5
19-9
(10-0)
9-5
(40)
15-8
(4-5)
5-4
(25)
80
(4-5)
3-5
(2-9)
43-7
(157)
18-4
(8-7)
204 mg/1 for clavulanic acid at 90 min. At 6 h, the mean plasma levels had fallen to 1-74
and 012 mg/1, respectively.
Urine concentrations
Urine samples collected prior to Augmentin administration contained no detectable
amoxycillin or clavulanic acid. The mean values (±S .D. ) of cumulative percentage of
dose recovered in the urine during the three 2-h intervals from time 0 to 6 h after dosing
are shown in Table II. Urine samples were available from 9 of the 11 study patients. By
6 h, 43-7 ± 15-7% of the dose of amoxycillin and 18-4 ± 8-7% of that of clavulanic acid
were recovered in the urine.
Pharmacokinetic data
The mean values (±S.D. ) of the important calculated pharmacokinetic parameters are
listed in Table III. The mean terminal plasma half-life was l-4h for amoxycillin and
10 h for clavulanic acid. The mean total plasma clearance rates expressed in relation
to body surface area were virtually identical, whereas the renal clearance rate for
amoxycillin was more than two times larger than the rate for clavulanic acid (321 versus
135 ml/min per 1-73 m2).
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Table in . Mean pharmacokinetic values (± SJO.)
Drug
amoxycillin
clavulanic
acid
Dosage
(mg/kg)
20
5
Plasma
half-
life
00
1-37
(05)
1-02
(04)
Area under
the
curve
(mg.h/1)
241
(88)
5-6
(1-5)
Total plasma
clearance
(ml/min per
1-73 mJ)
788
(337)
789
(249)
Renal
clearance
(ml/min per
1-73 m1)
321
(64)
135
(48)
Safety
Single doses of Augmentin syrup were well tolerated. Three patients complained of mild
nausea without vomiting at approximately 1 h after ingestion on an empty stomach. No
other adverse effects were reported.
Discussion
The observed plasma concentrations after the study dose of 20 mg of amoxycillin per kg
plus 5 mg of potassium clavulanate per kg (25 mg of Augmentin per kg) are comparable
when adjusted for dose to those reported with a different liquid suspension formulation
of Augmentin in children (Nelson, Kusmiesz & Shelton, 1982). Individual drug serum
concentrations show substantial variation as reflected in large S.D. values and broad
ranges of peak plasma concentrations of from 2-2 to 15-4 mg/1 for amoxycillin and from
0;6-to 3-5 mg/1 for clavulanic acid. Such individual variation of serum concentrations
with Augmentin in paediatric patients has been reported before (Nelson et al., 1982;
Beque et al., 1983; Stein & Gurwith, 1984) and should be considered as a potential
explanation in case of clinical failure of oral Augmentin therapy.
The mean of the observed peak concentrations of clavulanic acid (204mg/1) is
sufficient to render amoxycillin resistant strains of such paediatric pathogens as
Haemophilus inftuenzae, Staphylococcus aureus, H. Klebsiella aerogenes, together with
organisms such as Branhamella catarrhalis and Bacteroides fragilis sensitive to
amoxycillinXHunter«f a/., 1980).
The varying ratios of amoxycillin to clavulanic acid in plasma reflect slightly different
absorption, elimination and/or distribution characteristics of the two drug constituents.
The decreased ratios observed from 20 to 90 min after dosing suggest somewhat faster
absorption of the clavulanate. This might result in prompt /J-lactamase inhibition by
clavulanic acid at the site of infection allowing optimal prevention of amoxycillin
destruction by these bacterial enzymes.
The terminal plasma half-lives of clavulanic acid are always slightly shorter than those
of amoxycillin and amount to values close to 1 h; the average value in this study was
102 h. The renal clearance of amoxycillin was greater than that of clavulanic acid. The
values obtained were comparable to those reported in paediatric patients following
intravenous dosing (Schaad et al., 1983). The greater renal clearance of amoxycillin
-than of clavulanic acid is a consequence of the greater renal tubular secretion of
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amoxycillin, in spite of their comparable degrees of protein binding. Urine recovery of
amoxycillin and clavulanic acid in this study was lower than in studies in adult
volunteers following oral administration (Adam, de Visser & Koeppe, 1982). In the
absence of any data on the fraction of the dose absorbed it is not possible to distinguish
between the possible explanations of inter subject variation, reduced absorption or
greater non renal elimination compared with other patients.
Mild nausea approximately one hour after drug ingestion in three study patients most
probably was related to the administration on an empty stomach. The single doses of
Augmentin were otherwise well tolerated and loose stools or diarrhoea were not
observed. Palatability of the syrup formulation was judged as pleasant by all of the
children.
On the basis of these pharmacokinetic data in children, coupled with data on the in
vitro antimicrobial activity (Hunter et al., 1980; Reading et al., 1983) and the clinical
experience (Fleisher, Wilmott & Campos, 1983; Stein & Gurwith, 1984; Odio et al.,
1985), a dosage schedule of 25 mg of the studied syrup formulation of Augmentin per kg
body weight (20 mg of amoxycillin per kg plus 5 mg of potassium clavulanate per kg)
administered three times daily is recommended to treat various childhood bacterial
infections. These pharmacokinetic results in patients aged between 3 and 14 years
suggest that Augmentin syrup is a potentially useful drug formulation for treatment of
acute otitis media, sinusitis, cellulitis, urinary-tract infection, and bronchopneumonia of
suspected bacterial aetiology in paediatric patients in this age range.
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